EHC:NYE-Encompass Health Corp (USD)

COMMON STOCK | Medical Care Facilities |

Last Closing

USD 96.64

Change

+0.63 (+0.66)%

Market Cap

USD 9.66B

Volume

0.61M

Analyst Target

USD 86.07
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap
HCA HCA Holdings Inc

+3.15 (+0.78%)

USD 104.23B
UHS Universal Health Services Inc

-0.91 (-0.40%)

USD 16.11B
THC Tenet Healthcare Corporation

+2.98 (+1.83%)

USD 16.10B
DVA DaVita HealthCare Partners Inc

+0.85 (+0.52%)

USD 13.68B
CHE Chemed Corp

+1.93 (+0.32%)

USD 8.90B
ENSG The Ensign Group Inc

-0.29 (-0.20%)

USD 8.23B
CON Concentra Group Holdings Paren..

-0.06 (-0.27%)

USD 2.93B
ARDT Ardent Health Partners, Inc.

+0.08 (+0.44%)

USD 2.59B
NHC National HealthCare Corporatio..

+1.76 (+1.42%)

USD 1.96B
AMN AMN Healthcare Services Inc

-0.18 (-0.42%)

USD 1.62B

ETFs Containing EHC

SSPX Janus Henderson U.S. Sust.. 3.18 % 0.00 %

-0.07 (-0.15%)

USD 9.05M
HLTH:AU VanEck Global Healthcare .. 2.35 % 0.00 %

-0.17 (-0.15%)

USD 0.06B
XHS SPDR® S&P Health Care Se.. 2.09 % 0.35 %

+0.62 (+-0.15%)

USD 0.08B
JPSV Jpmorgan Active Small Cap.. 1.82 % 0.00 %

+0.23 (+-0.15%)

USD 0.02B
XMLV Invesco S&P MidCap Low Vo.. 1.41 % 0.25 %

+0.25 (+-0.15%)

USD 0.83B
ENG:PA BNP Paribas EASY ECPI Glo.. 1.06 % 0.00 %

-0.26 (-0.15%)

USD 0.22B
XU61:F BNP Paribas Easy SICAV - .. 1.06 % 0.00 %

-0.05 (-0.15%)

USD 0.24B
XU61:XETRA BNP Paribas EASY ECPI Glo.. 1.06 % 0.00 %

-0.42 (-0.15%)

USD 0.27B
ENGUS:PA BNP Paribas Easy ECPI Glo.. 1.06 % 0.00 %

-0.02 (-0.15%)

N/A
JMEE JPMorgan Market Expansion.. 0.59 % 0.00 %

+0.11 (+-0.15%)

USD 1.39B

Market Performance

  Market Performance vs. Industry/Classification (Medical Care Facilities) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 44.84% 69% C- 95% A
Dividend Return 0.45% 27% F 6% D-
Total Return 45.29% 65% D 94% A
Trailing 12 Months  
Capital Gain 45.00% 50% F 87% B+
Dividend Return 0.68% 27% F 7% C-
Total Return 45.67% 50% F 86% B+
Trailing 5 Years  
Capital Gain 59.21% 66% D+ 73% C
Dividend Return 7.05% 38% F 21% F
Total Return 66.26% 61% D- 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.09% N/A N/A 59% D-
Dividend Return 7.41% N/A N/A 55% F
Total Return 1.33% N/A N/A 31% F
Risk Return Profile  
Volatility (Standard Deviation) 24.31% N/A N/A 43% F
Risk Adjusted Return 30.50% N/A N/A 48% F
Market Capitalization 9.66B 81% B- 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector